IntelGenx Reports Fourth Quarter and Full-Year 2017 Financial Results

IntelGenx Technologies (TSX-V:IGX) reported financial results for the fourth quarter and twelve-month periods ended December 31, 2017. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

As quoted in the press release:

“2017 was an important year, as we continued down the path to clinical and commercial success,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We have taken many important steps to support our efforts in pharmaceutical oral film development, manufacturing and commercialization, and remain on track for bringing our products to market. Moving forward, we believe that 2018 will represent a landmark period for IntelGenx, as we continue to advance our product pipeline, and begin clinical testing of our potentially groundbreaking Montelukast VersaFilm™ in Alzheimer’s patients.”

Click here to read the full press release.